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Abstract
Background: The linkages between neuroinflammation and Alzheimer’s disease (AD) pathogenesis are well established.
What is not, however, is how specific immune pathways and proteins affect the disease. To this end, we previously
demonstrated that transgenic over-expression of CCL2 enhanced microgliosis and induced diffuse amyloid plaque
deposition in Tg2576 mice. This rodent model of AD expresses a Swedish b-amyloid (Ab) precursor protein mutant.
Methodology/Principal Findings: We now report that CCL2 transgene expression accelerates deficits in spatial and working
memory and hippocampal synaptic transmission in b-amyloid precursor protein (APP) mice as early as 2–3 months of age.
This is followed by increased numbers of microglia that are seen surrounding Ab oligomers. CCL2 does not suppress Ab
degradation. Rather, CCL2 and tumor necrosis factor-a directly facilitated Ab uptake, intracellular Ab oligomerization, and
protein secretion.
Conclusions/Significance: We posit that CCL2 facilitates Ab oligomer formation in microglia and propose that such events
accelerate memory dysfunction by affecting Ab seeding in the brain.
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Introduction
Amyloid-b peptide (Ab) is the principal component of cerebral
amyloid deposition seen as the hallmark of Alzheimer’s disease
(AD). However, how plaques accumulate and how clearance is
affected by microglia is poorly understood. Early ultrastructural
studies suggest that microglia affect progression of cerebral
amyloidosis [1]. Such defective microglial clearance functions
have recently been supported by long-term in vivo imaging of
amyloid plaques. These studies demonstrated long-term stability of
amyloid deposits following Ab synthesis interruption by the Tet-off
system. This extravascular protein synthesis progresses even
though microglia are in close proximity to the newly developed
plaques [2,3]. Age-related microglial dysfunction for amyloid
clearance also correlates with enhanced expression of pro-
inflammatory cytokines and reduced phagocytosis [4]. In contrast,
recruitment of peripheral blood-borne macrophages into the brain
parenchyma dramatically enhances amyloid clearance, suggesting
the possibilities of contrasting roles of resident microglia and
recruited blood monocyte-derived perivascular macrophages for
amyloid clearance [5,6].
Monocyte chemotactic protein-1 (MCP-1/CCL2) is a b-
chemokine responsible, in part, for the chemotaxis of mononuclear
phagocytes (MP; microglia, peripheral monocytes and macro-
phages). CCL2 levels in the cerebrospinal fluid and sera are linked
to neurodegeneration. Indeed, the amount of CCL2 shows a
negative correlation with cognitive scores in mild cognitively
impaired (MCI) and AD patients [7]. These findings suggest that
elevated CCL2 is a very early event in AD pathogenesis [8]. In
order to elucidate the role of CCL2 in AD pathogenesis, we
developed APP/CCL2 mice [9]. These mice were made by
crossing an established Ab deposition mouse model (Tg2576) with
a CCL2 over-expressing mouse under the regulation of glial acidic
fibrillar protein (GFAP) promoter (JE-95) [10]. CCL2 over-
expression led to microgliosis and increased diffuse plaque
formation in APP/CCL2 bigenic mice. Interestingly, both
increased CCL2 signaling in our APP/CCL2 bigenic mice and
deficient CCL2 signaling in APP/CCR2
2/2 mice worsened AD
pathology in different manners [11]. We now posit that intrathecal
CCL2 expression (as observed in AD) accelerates beta-amyloid-
osis. By contrast, circulating ‘inflammatory’ (Ly6-C
hi/CCR2
+)
monocytes affect Ab clearance in APP transgenic mice.
PLoS ONE | www.plosone.org 1 July 2009 | Volume 4 | Issue 7 | e6197To address this apparent discrepancy we have now extended
our studies in two ways: (1) we evaluated hippocampal
neurophysiology, memory and cognition to establish the functional
importance of the neuropathologic endpoints; and (2) we assessed
whether microglia affect conversion of monomeric Ab to oligomer
form, a key step towards cognitive dysfunction and subsequent
fibril formation [12,13]. Accelerated neurodegeneration was found
in APP/CCL2 bigenic mice. Our findings are highly relevant to
AD pathogenesis, and direct inhibition of CCL2 signaling will
reduce microglial activation in a fashion that will both lower Ab
deposition and improve behavioral outcomes. Suppressing CCR2
function, by contrast, can exert an opposite effect by impairing Ab
metabolism and disease.
Results
Accelerated memory impairments in APP/CCL2 mice
Tg2576 mice exhibit impaired memory retention and memory
acquisition by 6 and 12 months of age, respectively, when tested by
hidden platform or by a radial arm water maze (RAWM) test [14].
A10-day RAWM task was employed to assess working (short-term)
memory in APP/CCL2, CCL2, APP, and WT mice at 2–3 and 8–
9 months of age but using the same mice. RAWM has been used
effectively with mice to measure hippocampal function [14,15]. In
this learning test paradigm, an average error number of less than
one by trial 4 (T4) or T5 is regarded as secured memory formation
or recall, respectively. All animal groups, including APP mice,
showed secured memory formation and recall except the APP/
CCL2 bigenic mice, at 2–3 months of age, when errors at T4 and
T5 were assessed (Fig. 1A). Average latency (or time to reach the
correct platform) was used, in parallel tests, to measure memory
formation and recall. As a reference, the average latencies at T4
and T5 were similar among all groups with the exception of a
significantly longer latency in APP/CCL2 mice (Fig. 1C). APP and
CCL2 mice have normal memory function at 2–3 months of age,
whereas APP/CCL2 mice have already developed memory
impairment. Consistent with previous reports, APP mice develop
memory impairments by 8–9 months when compared to age-
matched WT or CCL2 littermates (T4 and T5, Fig. 1B). However,
APP/CCL2 mice show more severe memory impairments as
determined by errors and latencies at T4 and T5, when compared
to APP, CCL2, or WT mice (Fig. 1B, D). These data suggest that
memory formation and retention were more significantly impaired
in APP/CCL2 than in APP mice as early as 2–3 months and were
sustained to 8–9 months. To rule out impairment of vision, motor
coordination, or motivation as causes for defective memory
formation we tested the same mice for balance beam behavior,
body weight, and voluntary swimming speed in the open field at
two different ages (Supporting information (SI) Fig. S1). The
numbers of crossed segments on the balance beam, indicative of
basic sensory-motor coordination, were significantly higher in
CCL2 groups when compared to the 8–9 months age groups.
Some differences in voluntary activity of animals among groups
were seen but did not correlate with the RAWM results. Lower
body weights were observed in the APP mice when compared to
WT animal groups at 2–3 months. Such weight differences were
also observed in the APP/CCL2 and APP groups when compared
to CCL2 mice at 8–9 months. Nonetheless, voluntary swimming
speeds of APP/CCL2 were similar to WT and CCL2. APP mice
swam faster than the WT group at 8–9 months excluding the
possibility that a lower body weight resulted in slower swimming
speeds. Overall, these data support the idea that learning and
memory formation do not affect swimming or locomotor function
at any mouse age. Thus, impaired working memory, measured by
errors and latency, was readily seen in APP/CCL2 mice.
Figure 1. Accelerated spatial learning impairment in APP/CCL2 mice. The same animals were tested by RAWM test at two different time
points: 2–3 (A and C) and 8–9 months of age (B and D). The numbers of animals were 9 APP/CCL2, 10 CCL2, 8 APP, and 10 WT mice (all littermates
from cross breeding of APP and CCL2 hemizygotes). The compiled average errors (A and B) and latency (C and D) of Trial 1-5 are shown. *, ** or ***
denotes p,0.05, 0.01 or 0.001 versus WT, #, ## or ### denotes p,0.05, 0.01 or 0.001 versus CCL2, and $, $$ or $$$ denotes p,0.05, 0.01 or 0.001
versus APP group, respectively, as determined by two-way ANOVA and Bonferroni posttests.
doi:10.1371/journal.pone.0006197.g001
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Previous studies demonstrated that APP mice display abnor-
malities in synaptic transmission and long-term potentiation (LTP)
[16,17,18,19]. Based on these observations, synaptic function in
WT and transgenic mice were measured to determine if there was
any functional impairment in the hippocampal CA1 region.
Paired-pulse facilitation (PPF), a measure of short-term synaptic
plasticity, was examined in 5–6-month-old WT, CCL2, APP, and
APP/CCL2 mice. These animals were not used in behavioral
analysis in order to minimize potential complications due to maze
training. PPF curves were generated at interpulse intervals of 20,
40, 80, 160, and 320 msec. Significant impairments were observed
in PPF at 20-, 160-, and 320-msec intervals in APP/CCL2 and at
20 msec in APP compared to WT mice (Fig. 2B). These results
support the notion that decreased presynaptic neurotransmitter
release is operative during the second stimulus in APP/CCL2
mice.
To investigate basal synaptic transmission, input-output curves
for field excitatory postsynaptic potentials (fEPSP) were measured
in the CA1 region of the hippocampus. WT mice showed smaller
fEPSP slopes at all stimulus intensities (Fig. 2D). The average
slopes of fEPSP at 270 mA stimulus intensity in WT and APP/
CCL2 mice were 0.9360.1 mv/msec (n=15 slices from 8
animals) and 1.4360.19 mv/msec (n=13 slices from 7 animals;
p,0.05), respectively. These data indicate that basal synaptic
transmission is enhanced in APP/CCL2 mice at 5–6 months of
age, suggesting the upregulation of postsynaptic neurotransmitter
receptors to compensate decreased presynaptic neurotransmitter
release as reported [20] [21].
APP/CCL2 mice show enhanced Ab deposition and
oligomer formation
We examined the Ab load in APP/CCL2 mice. As expected,
enhanced Ab deposition was seen in bigenic APP/CCL2 mice
when compared to APP mice at 9 and 14 months, and reflective of
our previous work (Fig. 3A–C, [9]). SDS-stable Ab oligomers are
responsible for LTP abnormalities and precede Ab deposition
[22]. This is followed by Ab-induced neurotoxicity, hippocampal
degeneration [23], and memory impairment in Tg2576 [13]. Ab
oligomers from Tg2576 or AD brains are linked to memory
impairments and synaptic loss [13,24]. Based on this information,
we examined whether Ab oligomers are increased in APP/CCL2
mice. This was assayed by dot blot analysis of ultracentrifuged
lysates using specific Ab oligomer antibodies (clones NU-1 [25]).
APP/CCL2 bigenic mice showed increased Ab oligomer accu-
mulation when compared to age-matched APP mice (Fig. 3D).
This was confirmed by Ab immunoblotting of the extracellular-
enriched fraction of brain lysates (Fig. 3E–G). The amounts of
Figure 2. Paired-pulse facilitation and input-output responses recorded in the CA1 region of mouse hippocampal slices. WT (n=15
slices from 8 animals), CCL2 (n=13 slices from 7 animals), APP (n=12 slices from 7 animals) and APP/CCL2 mice (n=14 slices from 7 animals) at 5–6
months of age were tested. (A) Superimposed sample traces of field excitatory postsynaptic potentials (fEPSPs) recorded in the CA dendritic field in
response to twin pulse stimulation of Schafer-collateral pathway at various interpulse intervals (as shown in B) in WT and APP/CCL2 mice. (B) Graph
plots of averaged paired-pulse facilitation (PPF) ratio at 20-, 40-, 80-, 160-, and 320-msec interpulse intervals in 5–6-month-old WT, CCL2, APP and
APP/CCL2 mice. A significant difference between WT and APP/CCL2 mice (*p,0.05) was found at 20-, 160-, and 320-msec intervals and WT versus
APP (#p,0.05) at 20-msec intervals as determined by ANOVA and Newman-Keuls post hoc (p,0.05). (C) Representative traces of superimposed
fEPSPs, evoked by single pulse stimulations at various intensities ranging from 30 to 300 mA with an increment of 30 mA, were recorded from slices of
WT, CCL2, APP and APP/CCL2 mice, respectively. (D) Averaged input-output curves generated using different stimulus intensities ranging from 0–
300 mAi n3 0mA increments as shown in C. Significant difference between WT and APP/CCL2 (*p,0.05) at the stimulus intensity of 270 mA was
determined by ANOVA and Newman-Keuls post hoc.
doi:10.1371/journal.pone.0006197.g002
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PLoS ONE | www.plosone.org 3 July 2009 | Volume 4 | Issue 7 | e6197Figure 3. Enhanced Ab oligomer formation and deposition in APP/CCL2 mice. (A) Frozen sections (10-mm thickness) of temporal cortex of
APP and APP/CCL2 mice at 9 and 14 months of age were immunostained by Ab antibody and visualized by DAB staining. Scale bar, 400 mm. (B and C)
Quantification of cortical Ab staining in APP and APP/CCL2 mice at 9 months of age (n=5 per group). Percent area occupied by immunoreactivity (C)
and numbers of plaques were measured. *** denotes p,0.001 vs APP/CCL2 as determined by Student’s t-test. (D) APP/CCL2 and APP mice were
sacrificed at 9 months of age and 2% SDS-soluble fractions were subjected to dot blot assay for Ab oligomer using NU-1 as described (each brain
sample per dot). Top panel is a representative dot blot image (3 representative dots per group out of n=6 per group). Bottom panel shows
quantification of band luminescent intensities (n=6 per group). * denotes p,0.05 vs APP/CCL2 as determined by Student’s t-test. (E–G) Identification
of Ab oligomers in the brains of APP and APP/CCL2 mice assessed by immunoprecipitation of Ab oligomers from extracellular-enriched fraction using
NU-1 anti-Ab oligomer monoclonal antibody and Western blot using biotinylated 6E10 anti-Ab monoclonal antibody. Oligomerized synthetic human
Ab1–42 peptide was used as a size marker and positive control of Ab oligomers (hAb42, left lane). Arrows indicate respective migration positions of
trimers (3-mer), pentamer (5-mer in box), hexamers (6-mer in box), octamer (8-mer), and nonamers (9-mer). Band luminescent intensities for trimers
(F) and pentamers (G) were quantified by Image J software. * or *** denotes p,0.05 or 0.001 as determined by Student’s t-test, respectively.
doi:10.1371/journal.pone.0006197.g003
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increased in APP/CCL2 bigenic mice but did not reach
significance (data not shown). The amounts of trimer (3-mer)
and pentamer (5-mer) were increased in APP/CCL2 bigenic mice
compared to APP mice (Fig. 3F, G). These data suggest that the
early onset of memory impairment is due to enhanced accumu-
lation of Ab oligomers in APP/CCL2 bigenic mouse brains.
CCL2 levels in the hippocampus of each of the transgenic
groups were analyzed. A 360 to 800-fold increase in levels of
CCL2 protein was observed in the hippocampus of APP/CCL2
and CCL2 mice (36.0 and 47.5 ng protein/mg brain protein,
respectively) when compared to APP and WT mice (99.9 and
58.9 pg/mg, respectively; SI Fig. S2). Ab deposits are associated
with astro- and micro- gliosis, which was enhanced in APP/CCL2
bigenic mouse brains compared to APP mice (Fig. 4A–L). This
suggested that CCL2 affects Ab oligomer formation in areas
adjacent to microglia accumulation.
CCL2 and tumor necrosis factor (TNF-a) enhance
intracellular Ab microglial oligomer formation
To determine the effect of brain CCL2 expression on Ab
aggregation, we tested Ab production, degradation and aggrega-
tion. Our prior works demonstrated that CCL2 does not affect
APP neuronal expression and Ab production, nor does it reduce
intracellular Ab degradation in bone marrow derived macrophag-
es in vitro or in APP/CCL2 bigenic mice in vivo [9,26]. Thus, we
examined if Ab aggregation, especially oligomer formation, is
enhanced after phagocytosis of monomeric Ab42 in microglia.
Here a new system to assay cell Ab aggregation was developed by
combinations of microglial culture with immunofluorescence and
fluorometry using 96-well tissue culture plates (see Materials and
Methods). To optimize incubation time and Ab concentration,
primary cultured mouse microglia were incubated with mono-
meric Ab42 at 1 or 10 mM for 0, 1, 24 and 72 h, followed by
immunofluorescence of aggregated Ab with Ab oligomer antibod-
ies (NU-2) and nuclear staining (Hoechst 3342). Quantification of
the fluorescent signals was made by fluorometry of the
immunostained cells in 96-well plates. We observed rapid Ab
oligomer formation in 1 h after the uptake of monomeric Ab42 in
microglia, and the intensity of Ab increased at 24 and 72 h for
10 mMA b42 (231.7% and 909.4% increase over 1 h time point),
although the intensity decreased at 24 and 72 h for 1 mMA b42
(61.3% and 48.7% decrease over 1 h time point) (Fig. 5A–B).
However, the number of nuclei was significantly reduced at 24 and
72 h after the administration of 10 mMA b42 (50.6 and 83.7%
reduction as compared to the 0 h time point, respectively). We
posit that this was most likely caused by the cytotoxicity at high
concentrations of Ab42 (Fig. 5C). However, 1 h incubation of
10 mMA b42 showed sufficient Ab oligomer immunofluorescent
intensity without cytotoxicity (Fig. 5B–C). Thus, a 1 h assay was
performed at 10 mMo fA b42.
Next, we examined the effect of CCL2 in microglia. As shown
in Fig. 6A–B, we observed rapid Ab oligomer formation 1 h after
the uptake of 10 mM monomeric Ab42 in microglia, which is
significantly enhanced by co-incubation with CCL2 or TNF-a.
Inactivation of endogenous or recombinant CCL2 using a
neutralizing antibody against CCL2 (CCL2 mAb) significantly
reduced oligomer formation (Fig. 6B), demonstrating its specific
induction through the CCL2 receptor. These findings were
confirmed by immunoblot analysis of cell lysate by NU-1 dotblot
assays (Fig. 7A) and 6E10 immunoblottings (Fig. 7C). We found
that the amount of monomer, dimer, tetramer, and 12-mer was
increased in CCL2-treated microglia as compared to control,
whereas the hexamer level was found unchanged (Fig. 7D–G). In
addition, secretion of Ab oligomer from Ab-phagocytized
microglia was also enhanced by CCL2 (Fig. 7B), demonstrating
that microglia can be a source of Ab oligomer formation. This is
consistent with the fact that a certain fraction of phagocytized Ab
aggregates can be secreted into extracellular fluid from primary
microglia, bone marrow- or monocyte-derived macrophages
[26,27,28]. The data, taken together, suggest that Ab aggregates
can be secreted and serve as Ab seeds for further plaque
formations. The entire process is enhanced by CCL2.
Discussion
We demonstrated that CCL2 is a potent enhancer of Ab
oligomerization, microglial accumulation, and cognitive dysfunc-
tion in an animal model of beta-amyloidosis. These findings are
secondary to Ab aggregation as over-expression of CCL2 alone
has no effect on cognitive function. The data support the idea that
CCL2 is a co-factor in Ab-induced memory impairment for APP
mice. The effect of Ab with CCL2 co-expression was also observed
for spatial learning, PPF, and input-output responses. PPF is a
measure of presynaptic function, thought to result from an
increase in transmitter release due to a calcium influx into the
presynaptic terminal during responses to an initial stimulus.
Although PPF is not a direct measure of the transmitter release
from the presynaptic terminals, the impairment of PPF suggests
that the presynaptic terminals in APP/CCL2 mice may be less
able to sustain neurotransmitter release with repetitive stimulation.
Moreover, significant enhancement of the input-output responses
in APP/CCL2 mice was observed at 270 mA stimulus intensities
when compared to WT mice. The enhancements of input-output
responses in APP/CCL2 could explain why Ab induces altered
intracellular calcium levels and membrane excitability by blocking
fast-inactivating potassium (A) currents [29]. We have also
examined the hippocampal CA1 LTP evoked by tetanic
stimulation of the Schaffer collateral pathway using APP/CCL2,
APP, CCL2, and WT mice at 6 months of age, which did not
affect LTP impairments (data not shown). This suggests that the
effect of endogenously developed Ab oligomers is not sufficient to
induce LTP impairments and that 10-day RAWM tests are a more
sensitive measure to assay neuronal dysfunction.
Our previous study on APP/CCL2 mice demonstrated that
microglial accumulation enhances diffuse plaque formation,
suggesting the enhancement of Ab aggregation by CCL2. Indeed,
Ab oligomers are quantitatively elevated in APP/CCL2 mice as
compared to age-matched APP littermates in this study. Since Ab
oligomer levels directly correlate with memory impairment, it is
likely that CCL2 accelerates the onset of memory impairment by
enhancement of Ab oligomerization in the brain. However,
extracellular Ab oligomers in APP or APP/CCL2 bigenic mice
were undetectable using our system at 2–3 months of age (data not
shown). This suggests that very low amounts of Ab oligomer could
induce memory dysfunction in young mice, or, alternatively, a
combination of CCL2 and other inflammatory factors elicited by
Ab production (such as reactive oxygen species) may influence
memory formation. Indeed, Ab oligomers inhibit LTP induction
partly through microglial activation and inducible nitric oxide
synthase and superoxide formation [30]. Although the exact
mechanism behind how CCL2 enhances Ab oligomerization is
unknown, our data demonstrates that Ab uptake by microglia was
significantly enhanced by CCL2, which resulted in an increase of
oligomerized Ab species in both intracellular and extracellular
fractions. Microglia mediate Ab internalization through a non-
saturable, fluid phase macropinocytic mechanism. This mecha-
nism is distinct from phagocytosis and receptor-mediated endocy-
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possible that CCL2, which is a well-known chemoattractant
protein for microglia, may prominently activate cytoskeletal
dynamics as a part of its chemotactic signaling and coincidentally
affect Ab uptake. It should be noted that the NU-2 staining of
microglia is 70% preserved without cell permeabilization (data not
shown). This suggests that majority of the Ab aggregation seems to
take place on the cell surface rather than intracellularly. This is
also consistent with the fact that CCL2 rather suppresses Ab-
stimulated microglial phagocytosis [32]. Altogether, it is possible
that CCL2 mobilizes actin and tubulin cytoskeletal dynamics,
which enhance Ab uptake. In this manner, cell surface Ab can
rapidly aggregate to form Ab oligomers. We have previously
shown that Ab oligomer uptake was strikingly negligible as
compared to those of monomeric or fibrillar Ab in monocyte-
derived macrophages [28]. This suggests that oligomeric Ab will
dramatically lose its binding affinity to the membrane and be
secreted. This may be a mechanism for CCL2-mediated Ab
oligomer formation and Ab seeding for developing daughter
plaques surrounding the parent amyloid plaques.
We did not observe significant microgliosis in the hippocampus
prior to Ab deposition in the APP or APP/CCL2 mouse brain as
compared to non-Tg littermates, although we did see accumula-
tion of microglia surrounding either diffuse or compact plaques.
This is in contrast to the report of the APP/CCR2
2/2 mouse
study, which shows enhanced microgliosis in APP mice prior to the
parenchymal Ab deposition [11]. However, APP/CCR2
2/2 mice
develop accelerated amyloid angiopathy and shortened lifespans.
These data suggest the contrasting role of CCL2 to microglia and
peripheral monocytes. In brain parenchyma, CCL2 may enhance
microgliosis around amyloid depositions and enhance beta-
amyloidosis partly through Ab oligomer formation in microglia.
In periphery, CCL2 is a key molecule for the CNS recruitment of
circulating monocytes, which are 7/4
briLy-6G
2CCR2
+F4/80
+
[33] or Ly-6C
hiCCR2
+ [34], and play a critical role in amyloid
clearance [5]. Disruption of CCR2 leads to impaired mobilization
of monocytes from bone marrow and their CNS recruitment,
which will ultimately led to enhanced beta-amyloidosis. Thus
while brain CCL2 production may enhance beta-amyloidosis,
peripheral CCL2 will enhance clearance.
Neurodegeneration found in young APP/CCR2
2/2 mice
suggests the impaired neuroprotective effect of brain microglia
or recruited monocytes by disruption of CCR2. Although resting
microglia are neuroprotective, upon stimulation of innate
immunity mechanisms by a myriad of molecules, such as pro-
inflammatory cytokines and Toll-like receptor ligands, microglia
Figure 4. Accumulation of astrocytes and microglia to Ab deposits. Frozen sections (10-mm thickness) of temporal cortex of APP and APP/
CCL2 mice at 9 months of age were subjected to double immunofluorescence for GFAP (A–B, green) or IBA1 (C–D, green) and Ab (NU-1) (E-H, red). (I–
L) Merged images. Scale bar, 50 mm.
doi:10.1371/journal.pone.0006197.g004
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4 per well) were seeded in 96-well tissue culture plates,
and incubated with monomeric Ab42 (1 or 10 mM) in phenol red-free DMEM for 0 (-Ab), 1, 24, and 72 h, followed by washing, fixation, and
immunocytochemistry with NU-2 anti-Ab oligomer antibody (green) and Hoechst 33342 for nuclear staining (blue). (A) Representative phase and
merged immunofluorescet images after incubation with 10 mMA b42. Scale bar, 100 mm. (B, C) Fluorescent intensity of Ab (B) or nuclear (C) signals
were quantified using fluorometer (Ex/Em 488 nm/519 nm for Alexa 488, and 350 nm/461 nm for Hoechst 33342, respectively, n=3 per group). 21u
Ab represents negative control staining of microglia for Ab (B) or nuclear (C) staining using secondary antibody (Alexa 488 anti-mouse IgG) and
Hoeschst 33342 for nuclear staining. * or *** denotes p,0.05 or 0.001 versus 0 h incubation, respectively.
doi:10.1371/journal.pone.0006197.g005
CCL2-Enhanced Oligomerizaion
PLoS ONE | www.plosone.org 7 July 2009 | Volume 4 | Issue 7 | e6197convert to an inflammatory phenotype and become neurotoxic. In
accord, microglia in APP mice show pro-inflammatory activation
by aging [4]. Thus, suppression of CCL2 signaling in aged brains
may not develop adverse effects on neurons. Interestingly,
CCR2
2/2 mice showed enhanced noise-induced inner hair cell
loss, independent of CCL2 signaling, suggesting CCL2-indepen-
dent neuroprotective responses [35]. Thus, neutralization of
CCL2 in CNS should not affect the neuroprotective signaling of
CCR2 for therapeutic invention, and CNS suppression of
chemokine-mediated microgliosis through chemokine inhibitors
may be of therapeutic interest. Other chemokines, such as IL-8,
upregulated in MCI and AD patients, are likely to have similar
functions in microgliosis and cognitive dysfunction for APP mice.
The functions of these other chemokines need to be a focus of
future investigations. The cumulative prediction was that
increased intrathecal CCL2 would be deleterious for APP
transgenic mice. Further study will be necessary to determine
how blockage of brain CCL2 affects AD progression in affected
people.
Materials and Methods
Animals
All the animal studies followed guidelines and were approved by
the Institutional Animal Care and Use Committee at University of
Nebraska Medical Center. The transgenic mice used in this study
were described previously [9]. Briefly, Tg2576 mice expressing the
Swedish mutation of human APP695 were obtained from Drs. G.
Carlson and K. Hsiao-Ashe through Mayo Medical Venture [36].
Both Tg2576 mice and CCL2 (JE-95 strain) mice were
backcrossed at least four times to 129/Sve mice to develop a
129/Sve strain. Male Tg2576 were crossed with CCL2 females to
generate WT (APP and CCL2 transgene negative), CCL2 (APP
transgene negative and CCL2 transgene positive), APP (APP
transgene positive and CCL2 transgene negative), and APP/
CCL2 (APP and CCL2 transgene positive) mice. The APP, APP/
CCL2, WT, and CCL2 mice were littermates.
Genotyping
DNA samples were prepared from cut tail tips (,1.0 cm) of
individual pups, and genomic DNA was extracted using the Easy
DNA kit (Invitrogen). PCR was performed as described previously
to identify APP transgene-positive mice [37]. The human GFAP
promoter murine CCL2 transgene was confirmed by PCR of
genomic DNA with primers: JE-5 (59-TTC CTG GGC ACA
GGC TGA ATA GAG) and JE-3 (59-ATT GAG CAG GGG
GCT TGC ATT G), which amplify a 150 bp DNA fragment from
the transgene, but not the endogenous murine CCL2 gene as
described [9,10].
Weight, balance beam, and swimming speed monitoring
Weight was measured, balance beam test was performed and
the swimming speed was determined for all the mice run through
the 10-day RAWM test. For the balance beam task, each animal
was placed at the center of a suspended beam that is segmented at
10 cm intervals (100 cm in length) and released as described [14].
Whether the mice fell off the platform and the number of segments
crossed for each trial (3 min) was recorded. For subsequent
analysis of swimming speed the inserts were removed from the
tank used for RAWM and tracking software (PolyTrack, San
Diego Instruments) recorded the path of the rodent by light/dark
contrast detection by a video camera (Burle Securities) suspended
170 cm above the liquid surface as described [38].
Ten-day RAWM test
Mice at 2–3 and 8–9 months of age (9 APP/CCL2, 10 CCL2, 8
APP, and 10 WT mice) were introduced into the perimeter of a
circular water-filled tank 91 cm in diameter and 110 cm in height
with triangular inserts placed in the tank to produce six swim paths
Figure 6. CCL2 and TNF-a enhances Ab aggregation in mouse microglia. (A) Primary mouse microglia were incubated without Ab (-Ab), with
Ab (other panels), and co-incubated with 10 ng/ml CCL2, with 10 ng/ml TNF-a, with 1 mg/ml neutralizing anti-CCL2 antibody (CCL2 mAb), or co-
incubated with 10 ng/ml CCL2 and 1 mg/ml CCL2 mAb (CCL2+CCL2 mAb) for 1 h, followed by immunofluorescence with NU-2 anti-Ab oligomer
antibody (green) and Hoechst33342 for nuclear staining (blue). Merged captured images were shown. Insets are high-magnification. Scale bar,
100 mm. (B) Flurolometric quantification of Ab oligomer fluorescent signal (Ex/Em=488 nm/519 nm) normalized by the nuclear staining signal (Ex/
Em=350 nm/461 nm, n=3 per group). White or black bars represent incubation of microglia with no Ab (white, negative control) or with 10 mM
Ab42 (black) Ab, respectively. *** and ### denote p,0.001 versus Ab group, and versus CCL2 group, respectively.
doi:10.1371/journal.pone.0006197.g006
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correctly orient themselves were present on the walls of the tank.
At the end of one arm a 10 cm circular hidden plexiglass platform
was placed, submerged 1 cm deep. The platform was located in
the same arm for 4 consecutive acquisition trials (T1 through T4),
and in a different arm on different days. For T1-T4, the mouse
started the task from a different randomly chosen arm, excluding
the arm with the platform. Each trial lasted 1 min and an error
was scored each time when the body of the mouse, excluding tail,
entered the wrong arm, entered the arm with the platform but did
not climb on it, or did not make a choice for 15 sec. After T1
through T4 the mouse was returned to its cage for 30 min, and
then administered a retention trial (T5). For the retention trial the
start arm was the same as in T4. Each trial ended when the mouse
climbed onto and remained on the hidden platform for 10 sec.
The time taken by the mouse to reach the platform was recorded
as its latency. If the mouse did not reach the platform, 60 sec was
recorded as its latency and the mouse was gently guided to the
submerged platform. The mouse was given 20 sec to rest on the
platform between each trial from T1 through T4. Testing was
considered complete when WT mice reached asymptotic perfor-
mance (one error on T4 and T5; 10 training days). The errors for
the last 3 days of testing of each mouse were averaged and used for
statistical analysis.
Hippocampal slices and electrophysiology
Five to six-month-old transgenic and WT mice were anaesthe-
tized with isoflurane, decapitated, and their brains quickly
removed from the cranial cavity. The brains were placed into an
ice-cold (4uC) oxygenated artificial cerebrospinal fluid (ACSF)
environment. The hippocampi were dissected free and 400 mm-
thick (transverse section in hippocampus) slices were cut using a
tissue chopper. The slices were stored in a humidified/oxygenated
holding chamber at room temperature for at least 1 h before being
transferred into a recording chamber. In the recording chamber,
single hippocampal slices were fully submerged in a continuously
perfused ACSF solution at a constant flow rate of 2 ml/min with
the use of a peristaltic pump (Rainin Instruments). The ACSF
contained (in mM): NaCl (124.0), KCl (3.0), CaCl2 (2.0), MgCl2
(2.0), NaH2PO4 (1.25), NaHCO3 (26.0) and glucose (10.0). ACSF
Figure 7. CCL2 accelerates intracellular Ab microglial oligomer formation. (A, B) Quantification of Ab oligomers in mouse microglia (A), or
secreted from mouse microglia (B), incubated without Ab (-Ab), with Ab (+Ab), and co-incubated with CCL2 (10 ng/ml, Ab+CCL2) for 1 h, assessed by
dot blot. Band luminescent intensities were quantified by Typhoon Phosphoimager. ** denotes p,0.01 as determined by Student’s t-test. (C)
Identification of Ab oligomers in mouse microglia assessed by Western blot. Synthetic human Ab1–42 peptide (hAb42) was used as a size marker and
positive control (left lane). Arrows indicate respective migration positions of monomers (1-mer), dimers (2-mer), tetramers (4-mer), hexamers (6-mer)
and dodecamers (12-mer). Band luminescent intensities for monomers (D), dimers (E), tetramers (F), and dodecamers (G) were quantified by Image J
software. *, **, or *** denotes p,0.05, 0.01, or 0.001 as determined by Student’s t-test, respectively.
doi:10.1371/journal.pone.0006197.g007
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7.5. The temperature of the perfusion was maintained at 3061uC
with an automatic temperature controller (Warner Instruments).
Field excitatory post-synaptic potentials (fEPSPs) were generat-
ed by test pulses applied every 20 sec (low frequency) with a
constant current stimulation (100–300 mA, 40 msec in duration) of
Schaffer collateral-commissural axons using an insulated bipolar
tungsten electrode (except for the tip). The intensity and duration
of stimulation were adjusted to generate approximately 30–40% of
a maximal response. The evoked fEPSPs were recorded with an
Axopatch-1D amplifier (Axon Instruments, Inc.) in the CA1
dendrite field. The recording microelectrodes were made from
borosilicate glass capillaries with inner filaments that enable quick
back-filling as described [39,40]. The tip diameter of the
microelectrode was about 5.0 mm and had a resistance of 1–
5M V when filled with ACSF.
Input-output tests were conducted using fixed pulse duration of
40 msec with stimulation intensities increasing from 30 to 300 mA
in increments of 30 mA. Paired-pulse facilitation (PPF) was assessed
with twin pulses at a fixed pulse duration of 40 msec and a varying
interpulse interval (20, 40, 80, 160, 320 msec). The paired pulses
were delivered at 20-sec intervals and six consecutive responses
were averaged for each PPF test. The degree of facilitation was
determined as the increase in ratio of the initial slope of the second
response over first response in each pair.
Protein extraction and ELISA
CCL2 ELISA was performed as described previously [9,27].
Briefly, brain tissues were homogenized in solubilization buffer
(50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 2 mM EDTA-Na,
1% Triton X-100, and protease inhibitor cocktails (Roche Applied
Science)) and supernatant was subjected to CCL2 ELISA (Mouse
JE/CCL2, R&D System) [41].
Dot blot
Dot blot analysis for Ab oligomer was performed as described
previously [42] with some modifications. Briefly, mouse brains
were homogenized in 2% SDS containing phenylmethylsulfonyl
fluoride (PMSF) (0.5 mM), leupeptin (3 mg/ml) and aprotinin
(5 mg/ml), and centrifuged at 4uC for 1 h at 100,000 x g. Primary
mouse microglia were lysed with lysis buffer containing 50 mM
Tris-HCl (pH 7.6), 0.01% NP-40, 150 mM NaCl, 2 mM EDTA,
0.1% SDS, 0.1% Triton X-100, 1 mM PMSF, Leupeptin (3 mg/
ml) and Aprotinin (5 mg/ml), incubate 4uC for 1 h, and
centrifuged at 4uC for 10 min at 14,000 x g. Protein concentration
of the supernatant was determined using BCA Protein Assay Kit
(Pierce). Samples were adjusted with 16 PBS to the same
concentration, and 2 mg (brain) and 10 mg (microglia) of the
lysates were applied to a nitrocellulose membrane using Bio-DotH
SF Microfiltration Apparatus according to manufacture’s instruc-
tion (Bio-Rad). After blotting, the membrane was incubated in 16
PBS at 97uC for 10 min, washed in Tris-buffered saline (TBS,
pH 7.2) twice, then incubated in a 5% solution of nonfat dry milk
for 1 h at room temperature. After overnight incubation at 4uC
with anti-Ab oligomer antibody (clone NU-1; 1 mg/ml) [25], the
membrane was washed in Tween 20-TBS (TTBS) (0.05% Tween
20, 100 mM Tris-HCl (pH 7.5), 150 nM NaCl) for 3610 min and
incubated at room temperature with the HRP-conjugated anti-
mouse IgG (Jackson ImmunoResearch Laboratories) for 1 h. The
membrane was washed in TTBS for 3610 min and incubated for
5 min with a chemiluminescent substrate (ECL Plus, GE
Healthcare Bio-Sciences). Images were taken using an image
analyzer (Typhoon, Amersham Biosciences). Band density was
measured using ImageQuant software.
Immunoprecipitation and Western blot
Protein extraction of extracellular-enriched fraction and West-
ern blot analysis for Ab peptides was performed as described
previously [13] with some modifications. 500 mg of protein per
brain sample were incubated with NU-1 antibody in RIPA buffer
(10 mM Tris-HCl (pH 7.4), 100 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100, 10% glycerol, 0.1% SDS, 0.5%
deoxycholate, 1 mM PMSF, Leupeptin (3 mg/ml) and Aprotinin
(5 mg/ml)) at 4uC for 1 h, followed by incubation with 40 mlo f
Protein A/G Plus agarose (Santa Cruz Biotechnology) at 4uC for
overnight. Precipitants were washed four times with ice-cold RIPA
buffer, and reconstituted with 24 ml of sample buffer, then
incubated at 95uC for 3 min. 12 ml of immunoprecipitated sample
from the brain or 20 mg of protein from microglia was
electrophoresised on 16% SDS-polyacrylamide Tris-Tricine gel
[43]. Proteins were transferred to 0.2 mm PVDF membrane (Bio-
Rad). Membrane was blocked in 5% skim milk or 2% BSA/TBST
(Tris-Buffered Saline-Tween 20), and incubated with pan-Ab
monoclonal antibody (6E10) or biotinylated 6E10 (Signet),
followed by incubation with HRP-conjugated anti-mouse IgG
(Jackson ImmunoResearch Laboratories) or HRP-conjugated
streptavidin (Sigma). Blots were developed with West Pico
supersignal chemiluminescent substrate (Pierce). Band luminescent
intensities were quantified by ImageJ (NIH shareware program).
Immunohistochemistry
Immunohistochemistry was performed as described previously
[9,27]. Briefly, mice were euthanized with isoflurane and perfused
transcardially with 25 ml of ice cold PBS. The brains were rapidly
removed, immersed in freshly depolymerized 4% paraformalde-
hyde for 48 h, and cryoprotected by successive 24 h immersions in
15% and 30% sucrose in 16PBS immediately before sectioning.
Fixed, cryoprotected brains were frozen and sectioned in the
horizontal plane using a Cryostat (Leica), with sections collected
serially. Immunohistochemistry was performed using specific
antibodies to identify astrocyte (GFAP, rabbit polyclonal, 1:2000,
DAKO), microglia (IBA1, rabbit polyclonal, 1:1000, Wako), and
Ab oligomer (NU-1, mouse monoclonal, 1 mg/ml [25]). Immu-
nodetection was visualized using Envision Plus (DAKO) with 3,39-
diaminobenzidine (Vector Laboratories) for Ab oligomer staining.
For immunofluorescence, Alexa FluorH488-conjugated anti-rabbit
IgG (H+L) and Alexa FluorH568-conjugated anti-mouse IgG
(H+L) (Invitrogen) were used as secondary antibodies. Images
were captured with a digital camera (DP71, Olympus) attached to
a Nikon Eclipse TE300 inverted microscope using DP Controller
and DP Manager (Olympus).
Ab aggregation assay
Primary cultured mouse microglia were prepared from WT day
0 newborn pups as described [26,27]. For microglia, 5610
4 cells
per well (in 96-well plate for immunofluorescence and microplate
reading), or 2610
5 cells per well (in 24-well plate for biochemistry)
were seeded for 1 week in Dulbecco’s modified eagle medium
(DMEM) supplemented with heat-inactivated 10% fetal bovine
serum (FBS), 50 mg/ml penicillin/streptomycin (all from Invitro-
gen) and M-CSF. Ab1242 (Ab42) peptide was commercially
purchased (Invitrogen), and monomeric Ab peptide was prepared
according to manufacturer’s instruction. Briefly, solid Ab42
peptide was dissolved in cold hexafluoro-2-propanol (HFIP) and
incubated at room temperature for 1 h. The HFIP was then
removed by evaporation, and the resulting peptide was stored as a
film at 220uC. The resulting film was dissolved in anhydrous
DMSO with an Ab42 final concentration of 250 mM, and then
diluted to 1 or 10 mM in phenol red-free DMEM supplemented
CCL2-Enhanced Oligomerizaion
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(all from Invitrogen) and M-CSF. After pre-incubation with
recombinant mouse CCL2 (10 ng/ml, R&D System), microglia
were incubated without Ab, with Ab, with Ab and CCL2 (10 ng/
ml), with Ab and TNF-a (10 ng/ml, R&D System), with Ab and
anti-CCL2 neutralizing antibody (1 ug/ml, R&D System), or with
Ab, CCL2 and anti-CCL2 neutralizing antibody for 1 h, then
fixed with freshly depolymerized 4% paraformaldehyde for
15 min for immunofluorescence. Standard immunofluorescence
was performed using Ab oligomer (NU-2 monoclonal, 1 mg/ml
[25]), and Alexa FluorH488-conjugated anti-mouse IgG (H+L)
(Invitrogen) as secondary antibody. Finally, cells were counter-
stained with Hoechst 33342 (1:1000, Invitrogen) and fluorescent
intensities measured by SpectraMAX M5 microplate reader
(Molecular Devices) at excitation and emission wavelengths (Ex/
Em) of 488 nm/519 nm for Alexa 488 and 350 nm/461 nm for
Hoechst 33342.
Statistics
All data were normally distributed and presented as mean
values6standard errors of mean (SEM). In case of multiple mean
comparisons, the data were analyzed by analysis of variances
(ANOVA), followed by Newman-Keuls (for one-way ANOVA) or
Bonferroni (for two-way ANOVA) multiple comparison test using
statistics software (Prism 4.0, Graphpad Software, Inc.). In case of
single mean comparison, data were analyzed by Student’s t-test. p
value of less than 0.05 was regarded as significant difference.
Supporting Information
Figure S1 Balance beam, body weight, and swimming speed.
Animals tested in Fig. 1 were examined using the balance beam
with the average number of crossed segments per 3 minutes per
animal shown for 2–3 (A) or 8–9 (B) months of age. The frequency
of falling per group is shown in parenthesis. Average body weight
of each group at 2–3 (C) or 8–9 (D) months of age, and average
swimming speed at open field at 2–3 (E) or 8–9 (F) months of age
were also tested. The average relative speed unit was determined
by post-image acquisition analysis of actual pixels moved per
second during the 60-second test. The numbers of mice tested
were the same as Fig. 1 for all ages. * or # denotes p,0.05 versus
WT or CCL2 group of the same age as determined by ANOVA
and Newman-Keuls post-hoc.
Found at: doi:10.1371/journal.pone.0006197.s001 (0.88 MB TIF)
Figure S2 CCL2 levels in the hippocampus at 5–6 months of
age. The hippocampus of APP/CCL2, APP, CCL2, and WT mice
at 5–6 months of ages (n=6) were dissected and subjected for
protein extraction in solubilization buffer. Murine CCL2 protein
levels were determined using mouse CCL2 ELISA as described in
the Material and Methods, respectively. *** denotes p,0.001
versus APP or CCL2 as determined by ANOVA and Newman-
Keuls post hoc.
Found at: doi:10.1371/journal.pone.0006197.s002 (0.80 MB TIF)
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